Resources
Evidence, insights, and practical guidance for patient engagement
New data reveals a 10% increase in prescription refills for hypertensive patients using Medisafe. Discover how the "on-app" MPR jumped 21.8% for patients previously struggling with adherence.
Can an app save lives? New clinical research shows Medisafe significantly improves medication adherence for CHD patients. See the data behind the 0.47 MMAS-8 boost.
Medisafe dramatically improved adherence for cohorts of users who historically struggled, because following an HIV regimen correctly is critical to helping people with the disease live full and long lives. The proportion of patients with MPR ≥ 0.80 increased from 82.3% pre-app to 88.6% on-app, a 7.7% relative increase
Medication non-adherence causes 125,000 deaths annually in the US. Learn how Medisafe’s ISPOR-presented research proves mobile technology can scale to lower healthcare costs and improve chronic disease outcomes.
These study results are consistent with Medisafe’s previously announced findings that its users are 86% adherent to their medication regimens, versus the WHO’s estimate of 50 percent for the nation as a whole.
Medisafe was the highest-scoring app of the 10 apps assessed using MARS and had the highest scores in engagement and aesthetics. It was found to be interesting, entertaining, highly interactive, and customizable. Medisafe was the only app rated as having some evidence supporting its effectiveness in nonrandomized studies.
Today, Medisafe shared preliminary results of a study performed by the leading global provider of information, innovative technology solutions and contract research services focused on healthcare data. The purpose was to understand the real impact of Medisafe on users’ medication adherence.
